---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-001013"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:45:06.021670+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics initiates $40M ATM equity offering with Leerink Partners

## Summary
- Entered into ATM equity sales agreement with Leerink Partners LLC for up to $40M in common stock.
- Prior ATM program with JonesTrading terminated; $26.4M had been sold under that program.
- Net proceeds for general corporate purposes, including preclinical studies and clinical trials.
- Leerink receives 3% commission on gross sales; Company has broad discretion over proceeds use.

## SEC filing metadata
- accession: 0001140361-25-001013
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125001013/0001140361-25-001013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125001013/ny20040461x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-001013
- JSON: https://secwatch.observer/filing/0001140361-25-001013.json
- Plain text: https://secwatch.observer/filing/0001140361-25-001013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.